Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugators (ADCs) consist of monoclonal antibodies (antibodies) that target tumor-specific antigens or tumor-associated antigens, coupled with different numbers of small cytotoxins (payloads) via linkers. Both the high targeting of monoclonal antibodies and the cytotoxic drugs have the dual advantages of high activity in tumor tissues.

Trastuzumab deruxtecan
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
  • $728
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Datopotamab deruxtecan
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
  • $1,060
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Disitamab vedotin
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
  • $347
In Stock
Size
QTY
Brentuximab vedotin
T76707914088-09-8
Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
  • $413
In Stock
Size
QTY
Sacituzumab govitecan
T778241491917-83-9
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
  • $455
In Stock
Size
QTY
Telisotuzumab vedotin
T778381714088-51-3
Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.
  • $239
In Stock
Size
QTY
Glembatumumab vedotin
T741781182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
  • $718
In Stock
Size
QTY
Enfortumab vedotin-ejfv
T780651346452-25-2
Enfortumab vedotin-ejfv (Padcev) is an ADC compound targeting Nectin-4 with anti-tumor activity, used in the study of urothelial carcinoma.
  • $835
In Stock
Size
QTY
TargetMol
Izeltabart Tapatansine
T9901A-084
Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.
  • $450
In Stock
Size
QTY
TargetMol
PF-06647263
T774621822383-65-2
PF-06647263 (anti-EFNA4-ADC) is an ADC compound targeting EFNA4, with anti-tumor activity, composed of an anti-EFNA4 antibody conjugated with calicheamicin, inducing significant tumor regression in TNBC xenografts.
  • $447
In Stock
Size
QTY
TargetMol
DEDN6526A
T77458
DEDN6526A (RG-7636) is a humanized ADC compound targeting endothelin B receptor (ETBR), which can be used to study melanoma.
  • $447
In Stock
Size
QTY
Belantamab mafodotin
T779032050232-20-5
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.
  • $297
In Stock
Size
QTY
ADC Control Human IgG1-McMMAF
T9901A-754
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) comprising the ADC antibody IgG1 Human IgG1 kappa, Isotype Control, and the payload McMMAF.
  • Inquiry Price
Size
QTY
Cantuzumab mertansine
T76939400010-39-1
Cantuzumab mertansine (SB-408075; huC242-DM1), an antibody-drug conjugate (ADC), comprises the potent maytansine derivative (DM1) linked to the humanized monoclonal antibody (huC242) targeting CanAg. Demonstrating cytotoxicity against colon cancer cells, this compound shows extensive antitumor effectiveness across various CanAg-positive human tumor xenografts [1] [2].
  • Inquiry Price
Size
QTY
Zilovertamab vedotin
T77186
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].
  • Inquiry Price
Size
QTY
REGN5093-M114
T9901A-768
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase, effectively inhibiting NSCLC cell proliferation and demonstrating antitumor activity in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and a tubulin-inhibiting linker-payload.
  • Inquiry Price
Size
QTY
Trastuzumab rezetecan
T9901A-2312924909-11-3
Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer.
  • Inquiry Price
Size
QTY
Sacituzumab tirumotecan
T9901A-2372768350-77-0
Sacituzumab tirumotecan (SKB264 MK-2870) is a TROP2ADC utilized in research studies targeting triple-negative breast cancer (TNBC).
  • Inquiry Price
Size
QTY
FZ-AD005
T9901A-239
FZ-AD005 is a DLL3-targeted ADC composed of the novel anti-DLL3 antibody FZ-A038 and a valine-alanine (Val-Ala) dipeptide linker. This compound is used for research in small cell lung cancer.
  • Inquiry Price
Size
QTY
ABBV-3373
T9901A-446
ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized TNF antibody adalimumab and a glucocorticoid receptor agonist. It is designed for use in research related to rheumatoid arthritis.
  • Inquiry Price
Size
QTY
Indatuximab ravtansine
T9901A-2241238517-16-2
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.
  • Inquiry Price
Size
QTY
Trastuzumab emtansine
T366471018448-65-1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2].
  • $1,320
Backorder
Size
QTY
Sofituzumab vedotin
T811331418200-58-4
Sofituzumab vedotin (DMUC5754A) is an antibody-drug conjugate (ADC) comprising an anti-MUC16 antibody linked to monomethyl auristatin E (MMAE) via a protease-cleavable linker, utilized for cancer research [1].
  • Inquiry Price
Size
QTY
Depatuxizumab mafodotin
T9901A-0271585973-65-4
Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].
  • $978
6-8 weeks
Size
QTY